Another FDA-approved HDAC inhibitor, panobinostat, increased PFS and showed a better benefit:risk profile in patients with relapsed or relapsed and refractory multiple myeloma in Phase 3 studies (San-Miguel et al., 2014; Richardson et al., 2016). This evidence concerns the gene HDAC9 and AL amyloidosis.